Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy

about

Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy

Item

http://www.wikidata.org/entity/Q38997171

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Insulin-Like Growth Factors an ...... se To Neoadjuvant Chemotherapy

@en

type

Item

label

Insulin-Like Growth Factors an ...... se To Neoadjuvant Chemotherapy

@en

prefLabel

Insulin-Like Growth Factors an ...... se To Neoadjuvant Chemotherapy

@en

P1476

Insulin-Like Growth Factors an ...... se To Neoadjuvant Chemotherapy

@en

P2093

Alena E Frolova

http://www.w3.org/2001/XMLSchema#string

Alisa B Villert

http://www.w3.org/2001/XMLSchema#string

Larisa A Kolomiets

http://www.w3.org/2001/XMLSchema#string

Liudmila V Spirina

http://www.w3.org/2001/XMLSchema#string

Natalia V Yunusova

http://www.w3.org/2001/XMLSchema#string

P2860

Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis

Cellular actions of the insulin-like growth factor binding proteins

Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.

Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.

Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma

The role of the IGF system in cancer growth and metastasis: overview and recent insights.

CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery.

The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer.

P304

5315-5320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.22034/APJCP.2016.17.12.5315

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Irina Kondakova

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28125879

http://www.w3.org/2001/XMLSchema#string

P932

5454676

http://www.w3.org/2001/XMLSchema#string